Eurosurv. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season

[tetano]

• Christa Smolarchuk[SUP]1,*[/SUP] , Carla Ickert[SUP]1,*[/SUP] , Nathan Zelyas[SUP]2[/SUP] , Jeffrey C Kwong[SUP]3,4,5,6,7[/SUP] , Sarah A Buchan[SUP]3,4,5,8,9[/SUP]

Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58–64) against influenza A(H1N1), 49% (95% CI: 28–63) against influenza A(H3N2) and 75% (95% CI: 58–85) against influenza B.
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.2.2300709